Oncology Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Oncology Institute
TOI Stock  USD 3.56  0.09  2.47%   
Oncology Institute's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oncology Institute's valuation are provided below:
Gross Profit
63.8 M
Profit Margin
(0.16)
Market Capitalization
288 M
Enterprise Value Revenue
0.9243
Revenue
424.4 M
We have found one hundred twenty available trending fundamental ratios for Oncology Institute, which can be analyzed and compared to other ratios and to its competitors. Traders should compare all of Oncology Institute recent fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 25.3 M. Enterprise Value is estimated to decrease to about 105.6 M

Oncology Institute Total Revenue

256.02 Million

Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 4.3 M or Interest Expense of 9.1 M, as well as many indicators such as Price To Sales Ratio of 0.0644, Dividend Yield of 0.0105 or PTB Ratio of 9.87. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Build AI portfolio with Oncology Stock
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.

Oncology Institute Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding76 M86.3 M68.3 M
Slightly volatile
Total Assets178.2 M198.6 M110.9 M
Slightly volatile
Other Current Liabilities12.3 M18.8 M8 M
Slightly volatile
Total Current Liabilities34.6 M60 M23.9 M
Slightly volatile
Total Stockholder Equity3.1 M3.2 M43.8 M
Pretty Stable
Other Liabilities6.7 M7 M8.3 M
Pretty Stable
Property Plant And Equipment Net21.7 M43.3 M11.6 M
Slightly volatile
Accounts Payable15.6 M28 M12.3 M
Slightly volatile
Cash40.3 M57.1 M20 M
Slightly volatile
Non Current Assets Total69.7 M69.3 M50.5 M
Slightly volatile
Non Currrent Assets Other397.3 K677.4 K242.5 K
Slightly volatile
Other Assets279.8 K548.5 K216.5 K
Slightly volatile
Cash And Short Term Investments60.3 M57.1 M27.6 M
Slightly volatile
Net Receivables34 M56 M24 M
Slightly volatile
Good Will12.1 M6.5 M13.9 M
Pretty Stable
Liabilities And Stockholders Equity178.2 M198.6 M110.9 M
Slightly volatile
Non Current Liabilities Total78 M134.4 M39.5 M
Slightly volatile
Inventory8.7 M11.5 M6.1 M
Slightly volatile
Other Current Assets5.5 M4.6 M2.7 M
Slightly volatile
Other Stockholder Equity141.5 M246.6 M68.3 M
Slightly volatile
Total Liabilities112.6 M194.5 M63.3 M
Slightly volatile
Property Plant And Equipment Gross53.9 M51.3 M15.1 M
Slightly volatile
Total Current Assets108.5 M129.3 M60.3 M
Slightly volatile
Capital Stock6.8 K7.2 K33 M
Slightly volatile
Non Current Liabilities Other106.9 K112.5 K2.1 M
Pretty Stable
Net Working Capital73.9 M69.2 M36.5 M
Slightly volatile
Intangible Assets14.7 M13.3 M19.8 M
Slightly volatile
Common Stock6.7 K9.2 K3.4 K
Slightly volatile
Property Plant Equipment10.3 M9.8 M4 M
Slightly volatile
Short and Long Term Debt Total79.9 M141.6 M41.4 M
Slightly volatile
Current Deferred Revenue5.7 M5.4 M3.2 M
Very volatile
Long Term Debt73.5 M107.1 M34.9 M
Slightly volatile
Short and Long Term Debt156.5 K164.7 K3.5 M
Slightly volatile
Short Term Debt5.3 M7.8 M5.4 M
Pretty Stable
Warrants368 M414 M451.9 M
Slightly volatile
Common Stock Total Equity4.2 K8.1 K2.4 K
Slightly volatile
Capital Surpluse194.5 M214.2 M175.1 M
Slightly volatile

Oncology Institute Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.3 M7.2 M2.8 M
Slightly volatile
Interest Expense9.1 M8.6 M2.2 M
Slightly volatile
Selling General Administrative130.2 M124 M47.7 M
Slightly volatile
Total Revenue256 M452.4 M190.8 M
Slightly volatile
Gross Profit47.1 M62.1 M36.4 M
Slightly volatile
Other Operating Expenses298.6 M521.6 M211 M
Slightly volatile
Cost Of Revenue208.9 M390.3 M154.3 M
Slightly volatile
Total Operating Expenses89.7 M131.2 M56.7 M
Slightly volatile
Reconciled Depreciation4.2 M7.2 M2.8 M
Slightly volatile
Selling And Marketing Expenses33.3 M37.4 M40.9 M
Slightly volatile

Oncology Institute Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow26.9 M38.5 M13.9 M
Slightly volatile
Depreciation4.3 M7.2 M2.8 M
Slightly volatile
Capital Expenditures3.1 M4.4 M1.9 M
Slightly volatile
End Period Cash Flow34.7 M57.1 M18.4 M
Slightly volatile
Stock Based Compensation14.9 M12.8 M6.5 M
Slightly volatile
Cash Flows Other Operating6.9 M6.6 M1.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.06440.06783.6152
Slightly volatile
Dividend Yield0.01050.01180.0129
Slightly volatile
PTB Ratio9.877.4312.0207
Slightly volatile
Days Sales Outstanding34.4440.6537.9336
Slightly volatile
Book Value Per Share0.05220.0550.66
Pretty Stable
Average Payables8.6 M9.7 M10.6 M
Slightly volatile
Stock Based Compensation To Revenue0.04590.04940.026
Slightly volatile
Capex To Depreciation0.570.540.6542
Pretty Stable
PB Ratio9.877.4312.0207
Slightly volatile
EV To Sales0.270.282.8528
Slightly volatile
Inventory Turnover30.5938.8830.9804
Pretty Stable
Days Of Inventory On Hand11.059.7212.0869
Slightly volatile
Payables Turnover12.0212.5614.2234
Very volatile
Sales General And Administrative To Revenue0.00130.00150.0016
Slightly volatile
Capex To Revenue0.00930.00870.0087
Slightly volatile
Cash Per Share0.620.60.3662
Slightly volatile
Payout Ratio1.661.872.0404
Slightly volatile
Days Payables Outstanding28.3530.0826.2181
Very volatile
Intangibles To Total Assets0.140.150.4402
Slightly volatile
Current Ratio2.461.942.1951
Slightly volatile
Receivables Turnover9.699.299.809
Slightly volatile
Shareholders Equity Per Share0.05220.0550.66
Pretty Stable
Debt To Equity32.4330.886.1925
Slightly volatile
Capex Per Share0.03250.04540.0264
Slightly volatile
Average Receivables12.8 M14.4 M15.7 M
Slightly volatile
Revenue Per Share2.694.722.6452
Slightly volatile
Interest Debt Per Share1.651.570.4961
Slightly volatile
Debt To Assets0.670.640.2945
Slightly volatile
Graham Number0.220.250.2764
Slightly volatile
Operating Cycle45.550.3650.0205
Slightly volatile
Price Book Value Ratio9.877.4312.0207
Slightly volatile
Days Of Payables Outstanding28.3530.0826.2181
Very volatile
Dividend Payout Ratio1.661.872.0404
Slightly volatile
Ebt Per Ebit0.981.240.9746
Very volatile
Company Equity Multiplier45.4843.319.4762
Slightly volatile
Long Term Debt To Capitalization0.910.870.3659
Slightly volatile
Total Debt To Capitalization0.920.870.4227
Slightly volatile
Debt Equity Ratio32.4330.886.1925
Slightly volatile
Quick Ratio2.261.761.9299
Slightly volatile
Cash Ratio0.880.860.5865
Slightly volatile
Cash Conversion Cycle24.8726.8224.6412
Slightly volatile
Days Of Inventory Outstanding11.059.7212.0869
Slightly volatile
Days Of Sales Outstanding34.4440.6537.9336
Slightly volatile
Price To Book Ratio9.877.4312.0207
Slightly volatile
Fixed Asset Turnover11.4112.0169.9518
Slightly volatile
Debt Ratio0.670.640.2945
Slightly volatile
Price Sales Ratio0.06440.06783.6152
Slightly volatile
Asset Turnover2.072.622.3202
Slightly volatile
Gross Profit Margin0.210.160.2105
Slightly volatile
Price Fair Value9.877.4312.0207
Slightly volatile

Oncology Institute Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap25.3 M26.7 M463.6 M
Slightly volatile
Enterprise Value105.6 M111.2 M480.4 M
Slightly volatile

Oncology Fundamental Market Drivers

Oncology Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Oncology Institute Financial Statements

Investors use fundamental indicators, such as Oncology Institute's revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncology Institute's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue5.4 M5.7 M
Total Revenue452.4 M256 M
Cost Of Revenue390.3 M208.9 M
Stock Based Compensation To Revenue 0.05  0.05 
Capex To Revenue 0.01  0.01 
Revenue Per Share 4.72  2.69 
Ebit Per Revenue(0.15)(0.18)

Currently Active Assets on Macroaxis

DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C
BACBank of America
CRMSalesforce
When determining whether Oncology Institute offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oncology Institute's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oncology Institute Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oncology Institute Stock:
How To Invest In Oncology
Details
Is Oncology Stock a good investment?
Details
What is Oncology Institute's Net Worth?
Details
Largest Health Care Equipment & Supplies Companies
View
Largest Health Care Equipment & Services Companies
View
Check out the analysis of Oncology Institute Correlation against competitors.
For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncology Institute. If investors know Oncology will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncology Institute listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.67)
Revenue Per Share
5.279
Quarterly Revenue Growth
0.215
Return On Assets
(0.17)
Return On Equity
(6.52)
The market value of Oncology Institute is measured differently than its book value, which is the value of Oncology that is recorded on the company's balance sheet. Investors also form their own opinion of Oncology Institute's value that differs from its market value or its book value, called intrinsic value, which is Oncology Institute's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncology Institute's market value can be influenced by many factors that don't directly affect Oncology Institute's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Oncology Institute's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncology Institute is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncology Institute's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY